YARALI KOLIT CHASTOTASI VA XAVF OMILLARINI O’RGANISH BO’YICHA ADABIYOTLAR SHARHI
Keywords:
yarali kolit, erkaklar, epidemiologiya, xavf omillari, Andijon viloyati.Abstract
Maqolada yarali kolitning tarqalish chastotasi va asosiy xavf omillarini Andijon viloyati sharoitida o‘rganishga rejalashtirilgan. Adabiyotlar tahlili asosida kasallikning epidemiologik xususiyatlari, patogenezi, immunologik mexanizmlari hamda erkaklarga xos klinik kechish jihatlari bir qancha mualliflar tomonidan o’rganilganligi yoritildi. Yarali kolit rivojlanishida genetik moyillik, ichak mikrobiotasi buzilishi, noto‘g‘ri ovqatlanish, stress va zararli odatlarning ahamiyati ko‘rsatib berilgan izlanishlar natijasi sharhlandi. Andijon viloyatida hududiy epidemiologik tadqiqotlar o‘tkazish zarurligi asoslab berildi.
References
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–429.
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–1725.
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619.
Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2017;14:179–190.
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–342.
Frank DN et al. Molecular phylogenetic characterization of microbial community imbalances in IBD. PNAS. 2007;104(34):13780–13785
. 7.Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–638.
Vavricka SR et al. Gender differences in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(4):727–738. 22
Bikbavova GR, Livzan MA. Modulation of intestinal microbiome in ulcerative colitis. Ann Russ Acad Med Sci. 2020;75(6):577–584.
Sartor RB. Gut microbiota and inflammatory bowel diseases. Gastroenterology. 2008;134(2):577–594.
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
Ananthakrishnan AN. Environmental risk factors for IBD. Gastroenterology. 2015;149(5):1121–1135.
Dignass A et al. Second European evidence based consensus on ulcerative colitis. J Crohns Colitis. 2012;6(10):991–1030.
Harbord M et al. The first European evidence based consensus on extra intestinal manifestations. J Crohns Colitis. 2017;11(6):649–670.
Bernstein CN et al. Extraintestinal manifestations of IBD. Am J Gastroenterol. 2010;105:1237–1248.
Hou JK et al. Efficacy of treatments in IBD: systematic review. Am J Gastroenterol. 2011;106:644–656.
Mahid SS et al. Risk factors for ulcerative colitis: meta-analysis. World J Gastroenterol. 2006;12(37):6027–6030. 34
Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–951.
O‘zbekiston SSV va hududiy ma’lumotlar, 2019–2024. https://ssv.uz
Ng SC et al. Worldwide incidence and prevalence of IBD. Lancet. 2018;390(10114):2769–2778.
Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2017;14:179–190.
ECCO consensus: diagnosis & management of ulcerative colitis. J Crohns Colitis. 2017;11(6):649–670.
Hassan W et al. Probiotics for inflammatory bowel disease: effects and risks. Curr Med Chem. 2024;31(30):4807–4825.
Prevention of colorectal cancer in IBD. Pharmateca. 2021;28(7):8–14.
